Nuo Therapeutics, Inc.
AURX · OTCMCIK 1091596fmd_0DYFZ7XTEVZ7DGJT6WJ0KXKZP4Manufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
Loading
Open Financials Nuo Therapeutics, Inc. (AURX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $3.3 million | $1.4 million | +142.7% | 10-K 2026-03-30 · proof |
| Gross profit | $2.2 million | $1.1 million | +108.8% | 10-K 2026-03-30 · proof |
| Operating income | -$2.5 million | -$2.5 million | 10-K 2026-03-30 · proof | |
| Net income | -$2.5 million | -$2.3 million | 10-K 2026-03-30 · proof | |
| Cash from operating activities | -$864,971 | -$2.2 million | 10-K 2026-03-30 · proof | |
| Free cash flow | -$1.1 million | -$2.4 million | 10-K 2026-03-30 · proof |
- What was Nuo Therapeutics, Inc. (AURX)'s revenue in fiscal 2025?
- Nuo Therapeutics, Inc. (AURX) reported revenue of $3.3 million for fiscal 2025 (the year ended Dec 31, 2025), against $1.4 million the year before (+142.7%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Nuo Therapeutics, Inc. (AURX)'s gross profit in fiscal 2025?
- Nuo Therapeutics, Inc. (AURX) reported gross profit of $2.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $1.1 million the year before (+108.8%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Nuo Therapeutics, Inc. (AURX)'s operating income in fiscal 2025?
- Nuo Therapeutics, Inc. (AURX) reported operating income of -$2.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$2.5 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Nuo Therapeutics, Inc. (AURX)'s net income in fiscal 2025?
- Nuo Therapeutics, Inc. (AURX) reported net income of -$2.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$2.3 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Nuo Therapeutics, Inc. (AURX)'s cash from operating activities in fiscal 2025?
- Nuo Therapeutics, Inc. (AURX) reported cash from operating activities of -$864,971 for fiscal 2025 (the year ended Dec 31, 2025), against -$2.2 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Nuo Therapeutics, Inc. (AURX)'s free cash flow in fiscal 2025?
- Nuo Therapeutics, Inc. (AURX) reported free cash flow of -$1.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$2.4 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:AURX&period_type=annual&limit=5"Information only, not investment advice.